Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely ...

Healio sat down with Stockfelt to discuss the limitations of rituximab, the optimal SLE populations for B-cell depletion and the future of personalized medicine in the disease. Healio: Why did you ...

After B-cell depletion with rituximab, repletion of the peripheral B-cell compartment in patients with rheumatoid arthritis (RA) recapitulates events during B-cell ontogeny. In this context ...

The company’s phase 1b studies of its imvotamab antibody for arthritis and lupus flopped; CEO Dr. Mary Beth Harler wrote that “the depth and consistency of B cell depletion is insufficient to ...

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front ...

Interim data from early stage trials of the company’s imvotamab as a treatment for ... “show that the depth and consistency ...